DigestRedComo funciona
Red
/
Empresas
Av
No verificado

Avenzo Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

26 Comunicados de prensa

Ver todos los comunicados de prensa
10/09/2026
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Avenzo Therapeutics to Present Preliminary Phase 1 Study Results of AVZO-1418, a Potentially Differentiated EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
03/09/2026
Mercado laboral
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Avenzo Therapeutics Announces Appointment of Barbara Bodem and Elizabeth Mily to Board of Directors as Independent Directors
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
02/09/2026
Eventos
Web y redes sociales
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Avenzo Therapeutics to Participate in the Upcoming Wells Fargo 21st Annual Healthcare Conference
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
24/08/2026
Mercado laboral
Asociaciones/Profesionales
Oncología
Salud
Recursos Humanos
Farmacéutica
Biotecnología
Avenzo Therapeutics Announces Appointment of Connie Wedel as Chief Human Resources Officer
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
01/06/2026
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
28/05/2026
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Eventos
Industria
Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
28/04/2026
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Avenzo Therapeutics Advances the Combination of CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) in Ongoing Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
21/04/2026
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Avenzo Therapeutics to Present Updated Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
11/12/2025
Industria
Eventos
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
24/11/2025
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Industria
Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0